<?xml version='1.0' encoding='utf-8'?>
<document id="27161631"><sentence text="The Investigational Drug VT-1129 Is a Highly Potent Inhibitor of Cryptococcus Species CYP51 but Only Weakly Inhibits the Human Enzyme." /><sentence text="Cryptococcosis is a life-threatening disease often associated with HIV infection" /><sentence text=" Three Cryptococcus species CYP51 enzymes were purified and catalyzed the 14α-demethylation of lanosterol, eburicol, and obtusifoliol"><entity charOffset="95-105" id="DDI-PubMed.27161631.s3.e0" text="lanosterol" /><entity charOffset="107-115" id="DDI-PubMed.27161631.s3.e1" text="eburicol" /><entity charOffset="121-133" id="DDI-PubMed.27161631.s3.e2" text="obtusifoliol" /><pair ddi="false" e1="DDI-PubMed.27161631.s3.e0" e2="DDI-PubMed.27161631.s3.e0" /><pair ddi="false" e1="DDI-PubMed.27161631.s3.e0" e2="DDI-PubMed.27161631.s3.e1" /><pair ddi="false" e1="DDI-PubMed.27161631.s3.e0" e2="DDI-PubMed.27161631.s3.e2" /><pair ddi="false" e1="DDI-PubMed.27161631.s3.e1" e2="DDI-PubMed.27161631.s3.e1" /><pair ddi="false" e1="DDI-PubMed.27161631.s3.e1" e2="DDI-PubMed.27161631.s3.e2" /></sentence><sentence text=" The investigational agent VT-1129 bound tightly to all three CYP51 proteins (dissociation constant [Kd] range, 14 to 25 nM) with affinities similar to those of fluconazole, voriconazole, itraconazole, clotrimazole, and ketoconazole (Kd range, 4 to 52 nM), whereas VT-1129 bound weakly to human CYP51 (Kd, 4"><entity charOffset="161-172" id="DDI-PubMed.27161631.s4.e0" text="fluconazole" /><entity charOffset="174-186" id="DDI-PubMed.27161631.s4.e1" text="voriconazole" /><entity charOffset="188-200" id="DDI-PubMed.27161631.s4.e2" text="itraconazole" /><entity charOffset="202-214" id="DDI-PubMed.27161631.s4.e3" text="clotrimazole" /><entity charOffset="220-232" id="DDI-PubMed.27161631.s4.e4" text="ketoconazole" /><pair ddi="false" e1="DDI-PubMed.27161631.s4.e0" e2="DDI-PubMed.27161631.s4.e0" /><pair ddi="false" e1="DDI-PubMed.27161631.s4.e0" e2="DDI-PubMed.27161631.s4.e1" /><pair ddi="false" e1="DDI-PubMed.27161631.s4.e0" e2="DDI-PubMed.27161631.s4.e2" /><pair ddi="false" e1="DDI-PubMed.27161631.s4.e0" e2="DDI-PubMed.27161631.s4.e3" /><pair ddi="false" e1="DDI-PubMed.27161631.s4.e0" e2="DDI-PubMed.27161631.s4.e4" /><pair ddi="false" e1="DDI-PubMed.27161631.s4.e1" e2="DDI-PubMed.27161631.s4.e1" /><pair ddi="false" e1="DDI-PubMed.27161631.s4.e1" e2="DDI-PubMed.27161631.s4.e2" /><pair ddi="false" e1="DDI-PubMed.27161631.s4.e1" e2="DDI-PubMed.27161631.s4.e3" /><pair ddi="false" e1="DDI-PubMed.27161631.s4.e1" e2="DDI-PubMed.27161631.s4.e4" /><pair ddi="false" e1="DDI-PubMed.27161631.s4.e2" e2="DDI-PubMed.27161631.s4.e2" /><pair ddi="false" e1="DDI-PubMed.27161631.s4.e2" e2="DDI-PubMed.27161631.s4.e3" /><pair ddi="false" e1="DDI-PubMed.27161631.s4.e2" e2="DDI-PubMed.27161631.s4.e4" /><pair ddi="false" e1="DDI-PubMed.27161631.s4.e3" e2="DDI-PubMed.27161631.s4.e3" /><pair ddi="false" e1="DDI-PubMed.27161631.s4.e3" e2="DDI-PubMed.27161631.s4.e4" /></sentence><sentence text="53 μM)" /><sentence text=" VT-1129 was as effective as conventional triazole antifungal drugs at inhibiting cryptococcal CYP51 activity (50% inhibitory concentration [IC50] range, 0"><entity charOffset="42-50" id="DDI-PubMed.27161631.s6.e0" text="triazole" /></sentence><sentence text="14 to 0" /><sentence text="20 μM), while it only weakly inhibited human CYP51 activity (IC50, ∼600 μM)" /><sentence text=" Furthermore, VT-1129 weakly inhibited human CYP2C9, CYP2C19, and CYP3A4, suggesting a low drug-drug interaction potential" /><sentence text=" Finally, the cellular mode of action for VT-1129 was confirmed to be CYP51 inhibition, resulting in the depletion of ergosterol and ergosta-7-enol and the accumulation of eburicol, obtusifolione, and lanosterol/obtusifoliol in the cell membranes"><entity charOffset="118-128" id="DDI-PubMed.27161631.s10.e0" text="ergosterol" /><entity charOffset="133-147" id="DDI-PubMed.27161631.s10.e1" text="ergosta-7-enol" /><entity charOffset="172-180" id="DDI-PubMed.27161631.s10.e2" text="eburicol" /><entity charOffset="182-195" id="DDI-PubMed.27161631.s10.e3" text="obtusifolione" /><entity charOffset="201-211" id="DDI-PubMed.27161631.s10.e4" text="lanosterol" /><entity charOffset="212-224" id="DDI-PubMed.27161631.s10.e5" text="obtusifoliol" /><pair ddi="false" e1="DDI-PubMed.27161631.s10.e0" e2="DDI-PubMed.27161631.s10.e0" /><pair ddi="false" e1="DDI-PubMed.27161631.s10.e0" e2="DDI-PubMed.27161631.s10.e1" /><pair ddi="false" e1="DDI-PubMed.27161631.s10.e0" e2="DDI-PubMed.27161631.s10.e2" /><pair ddi="false" e1="DDI-PubMed.27161631.s10.e0" e2="DDI-PubMed.27161631.s10.e3" /><pair ddi="false" e1="DDI-PubMed.27161631.s10.e0" e2="DDI-PubMed.27161631.s10.e4" /><pair ddi="false" e1="DDI-PubMed.27161631.s10.e0" e2="DDI-PubMed.27161631.s10.e5" /><pair ddi="false" e1="DDI-PubMed.27161631.s10.e1" e2="DDI-PubMed.27161631.s10.e1" /><pair ddi="false" e1="DDI-PubMed.27161631.s10.e1" e2="DDI-PubMed.27161631.s10.e2" /><pair ddi="false" e1="DDI-PubMed.27161631.s10.e1" e2="DDI-PubMed.27161631.s10.e3" /><pair ddi="false" e1="DDI-PubMed.27161631.s10.e1" e2="DDI-PubMed.27161631.s10.e4" /><pair ddi="false" e1="DDI-PubMed.27161631.s10.e1" e2="DDI-PubMed.27161631.s10.e5" /><pair ddi="false" e1="DDI-PubMed.27161631.s10.e2" e2="DDI-PubMed.27161631.s10.e2" /><pair ddi="false" e1="DDI-PubMed.27161631.s10.e2" e2="DDI-PubMed.27161631.s10.e3" /><pair ddi="false" e1="DDI-PubMed.27161631.s10.e2" e2="DDI-PubMed.27161631.s10.e4" /><pair ddi="false" e1="DDI-PubMed.27161631.s10.e2" e2="DDI-PubMed.27161631.s10.e5" /><pair ddi="false" e1="DDI-PubMed.27161631.s10.e3" e2="DDI-PubMed.27161631.s10.e3" /><pair ddi="false" e1="DDI-PubMed.27161631.s10.e3" e2="DDI-PubMed.27161631.s10.e4" /><pair ddi="false" e1="DDI-PubMed.27161631.s10.e3" e2="DDI-PubMed.27161631.s10.e5" /><pair ddi="false" e1="DDI-PubMed.27161631.s10.e4" e2="DDI-PubMed.27161631.s10.e4" /><pair ddi="false" e1="DDI-PubMed.27161631.s10.e4" e2="DDI-PubMed.27161631.s10.e5" /></sentence><sentence text="" /></document>